Jazz Appears to Be Winner on Patent Claim Terms in Xyrem Suit

A district court judge has largely sided with Jazz Pharmaceuticals’ definitions for patents on its narcolepsy drug Xyrem, and the outcome looks like a “clear win” in Jazz’s legal struggle to prevent generic competition from Roxane Laboratories, one analyst says. The U.S. District Court for the District of New Jersey concurred with Jazz’s construction of the patent terms 17 times in its opinion on the disputed patent claims, Jefferies analyst Corey Davis writes. In contrast, he noted no instances of agreement with Roxane.
Washington Drug Letter